Cryoport launches Fusion 800: door‑friendly, LN₂‑free −150°C freezer for clinical labs

Cryoport unveils door‑friendly LN₂‑free freezer

Fusion 800 frees clinics and labs from liquid nitrogen infrastructure

Cryoport’s MVE Biological Solutions unit is rolling out the MVE Fusion 800 Series, a self‑sustaining cryogenic freezer that eliminates the need for continuous liquid nitrogen (LN₂) supply and targets constrained laboratory and clinical spaces. Announced on Feb. 11, 2026, the Fusion 800 maintains steady‑state temperatures at or below −150°C and is built on the award‑winning Fusion platform, offering energy‑efficient, LN₂‑free operation suited to storage of cell and gene therapies and other temperature‑sensitive biological materials.

The Fusion 800’s compact, lab‑sized design measures 32 inches wide, enabling it to fit through standard doorways and avoid costly facility modifications, a persistent barrier for many research facilities and hospital pharmacies. Cryoport and MVE describe the unit as providing high storage density and flexible formats — including vials, blood bags and cassettes — for clinical development operations, biorepositories and blood and tissue banks that lack traditional cryogenic infrastructure. Mike Duich, president and CEO of MVE Biological Solutions, calls the product “a major evolution” in access to ultra‑low temperature storage.

Cryoport frames the Fusion 800 as part of a broader strategy to reduce LN₂ handling risks and supply costs while enhancing safety and sustainability in the temperature‑controlled supply chain for regenerative medicine and biologics. Jerrell Shelton, Cryoport’s CEO, says the product “solves a longstanding challenge” by protecting critical biological materials and life‑saving therapies without legacy space and infrastructure requirements and is “on a path to becoming the new standard” in research facilities and hospital pharmacies worldwide.

Other developments and industry context

The Fusion 800 is recognized with the ISBER Outstanding New Product Award, underscoring industry interest in alternatives to liquid nitrogen‑based systems. Cryoport positions the unit for customers such as biopharmaceutical companies, CDMOs, CROs, clinics and hospital pharmacies that are increasingly handling cell and gene therapies requiring reliable ultra‑low temperature storage.

Cryoport continues to promote its integrated temperature‑controlled supply chain services alongside the Fusion 800, emphasizing compatibility with its logistics, monitoring and risk‑mitigation offerings. The company directs interested customers to mvebio.com or MVE distributors for specifications and deployment guidance.